Supply Chain Intelligence

TG Therapeutics, Inc. Supply Chain

TGTX supply chain intelligence for TG Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

TGTX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
10Customers
3Debt Items
20Related Chains

TG Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
CERTAIN-SUBSIDIARIES-OF-THE-BORROWER CERTAIN-SUBSIDIARIES-OF-THE-BORROWER 90% certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent
MXCT MaxCyte, Inc. 85% Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT g…
DTIL Precision BioSciences, Inc. 72% oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations. The Company's common stock is quoted on …
DTIL Precision BioSciences, Inc. 72% Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL g…

TG Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
NEURAXPHARM NEURAXPHARM 92% License, milestone, royalty and other revenue consist primarily of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm.
CUSTOMER-1 CUSTOMER-1 90% Three months ended March 31, 2026 Customer 1 42 % 39 %
CUSTOMER-2 CUSTOMER-2 90% Three months ended March 31, 2026 Customer 2 27 % 34 %
CUSTOMER-3 CUSTOMER-3 90% Three months ended March 31, 2026 Customer 3 20 % 16 %
CUSTOMER-4 CUSTOMER-4 90% Three months ended March 31, 2026 Customer 4 9 % 11 %
DTIL Precision BioSciences, Inc. 72% oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations. The Company's common stock is quoted on …
DTIL Precision BioSciences, Inc. 72% Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: oduct candidates. The Company may seek significant additional financing in the future to support strategic initiative…
MXCT MaxCyte, Inc. 72% Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial mil…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG…
NVSEF Novartis AG 72% all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG. ​ 13 Table of Contents TG-1701 (BTK inhibitor) ​ In January 2018, we entered into…

TG Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TGTX-DEBT-12967 Warrants outstanding: 147058 90% xbrl warrant detail from xbrl 2023-12-31.
TGTX-DEBT Debt stack $753.6M 90% Market cache reports total debt of $753.6M.
TGTX-DEBT-12968 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.

TG Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for TG Therapeutics, Inc..

TG Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
TGTX-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 368 tracked holders.

TG Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DB Deutsche Bank Aktiengesellschaft 100.00 2
TMO Thermo Fisher Scientific Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
CELU Celularity Inc. 100.00 2
ENGN enGene Therapeutics Inc. 100.00 2
FISI Financial Institutions, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
CMPS COMPASS Pathways plc 100.00 2
BIO Bio-Rad Laboratories, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
BBIO BridgeBio Pharma, Inc. 100.00 2
HBIO Harvard Bioscience, Inc. 100.00 2
IRON Disc Medicine, Inc. 100.00 2
SVRA Savara Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 1 ['customer', 'supplier']
DERM Journey Medical Corporation 100.00 2
ANAB AnaptysBio, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
KURA Kura Oncology, Inc. 100.00 2
View TGTX supply chain intel →

Explore the full interactive supply chain map for TG Therapeutics, Inc..

Open TGTX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map